Roche Holding AG has been subject to mixed analyst opinions, with sell ratings from J.P. Morgan and Deutsche Bank, hold ratings from Berenberg Bank, Barclays and HSBC, and buy ratings from Kepler Capital, UBS and BNP Paribas Exane. Roche's dividends have remained steady, with one increase to CHF 9.70, and
Analog Devices CEO Vincent Roche has sold shares worth $2 million. In the biotech sector, Roche has inked a $5.3 billion deal with
Zealand Pharma, leading to increased competition between Roche, Eli Lilly, and AstraZeneca and causing Novo Nordisk's stock to slide. The Swiss giant looks to challenge the weight-loss market, but shares have also fallen following the Ocrevus trial update and a possibility of side effects in its obesity pill trial. However, Roche has expanded AI in Digital Pathology and Drug Development, and solid Q1 2025 sales growth has been reported despite currency headwinds. Likewise, Roche has secured a Zealand obesity drug candidate for up to $5.3 billion and made significant investments in the U.S., with potential plans for a new drug manufacturing facility in North Carolina.
Roche Stocks News Analytics from Wed, 11 Sep 2024 07:00:00 GMT to Sat, 19 Jul 2025 05:43:36 GMT -
Rating 0
- Innovation 1
- Information 3
- Rumor -5
